• No results found

University of Groningen Developments in the treatment of advanced melanoma Sloot, Sarah

N/A
N/A
Protected

Academic year: 2021

Share "University of Groningen Developments in the treatment of advanced melanoma Sloot, Sarah"

Copied!
2
0
0

Bezig met laden.... (Bekijk nu de volledige tekst)

Hele tekst

(1)

University of Groningen

Developments in the treatment of advanced melanoma

Sloot, Sarah

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version

Publisher's PDF, also known as Version of record

Publication date: 2017

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Sloot, S. (2017). Developments in the treatment of advanced melanoma. University of Groningen.

Copyright

Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.

(2)

Dissertation propositions

1. Intralymphatic metastases are more prevalent after a sentinel node biopsy than after wide local excision alone (this dissertation)

2. The increase in intralymphatic metastasis after sentinel node biopsy in melanoma is caused by aggressive tumor behavior as opposed to entrapment of tumor cells due to interruption of lymph flow (this dissertation) 3. Treatment of metastatic melanoma has become more advanced with increased efficacy due to introducing new perfusion techniques, intralesional therapies and new systemic therapies (this dissertation) 4. For select locoregionally advanced patients, BRAF targeted therapy is a pro­ mising neoadjuvant strategy (this dissertation) 5. BRAF inhibitors don’t have direct carcinogenic effects, but rather potentiate preexisting initiating oncogenic events (this dissertation) 6. The prognosis of melanoma brain metastasis patients has vastly improved over the past decade which provides a better outlook for patients suffering from this disease (this dissertation) 7. Although the brain is still a common site for treatment failure in melanoma, the incidence of de novo brain metastasis does not differ based on treatment modality (this dissertation) 8. In the realm of ideas everything depends on enthusiasm… in the real world all rests on perseverance (Johann Wolfgang von Goethe) 9. Communication ­ the human connection ­ is the key to personal and career success (Paul J. Meyer)

10. The road to success is not easy to navigate, but with hard work, drive and passion, it’s possible to achieve the American dream (Tommy Hilfiger)

Sarah Sloot September, 2017

Referenties

GERELATEERDE DOCUMENTEN

Because the recurrence percentage of SLNB negative patients with ulcerated nodular melanoma approaches the recurrence percentage of SLNB positive melanoma patients,

behandeling van stadium III melanoom steeds beperkter, om kliermetastasen aan te kunnen tonen zal de SLNB op termijn worden vervangen door een minimaal invasief alternatief zoals

BRAF treatment in advancedmelanomaBRAF inhibition for advanced locoregional BRAF V600E mutant melanoma:. a potential neoadjuvant strategy

TVEC is an oncolytic, immune-enhanced herpes simplex virus type 1, selectively infecting cancer cells and destroying the cells by direct effects on metabolic processes

It starts out with answering the important question whether sentinel lymph node biopsy leads to more intralymphatic metastases, then gives an update on

Tumor Mitotic Rate Added to the Equation: Melanoma Prognostic Factors Changed?: A Single-Institution Database Study on the Prog- nostic Value of Tumor Mitotic Rate for Sentinel

Unresectable melanoma to the liver and unresectable in­transit disease in the limb pose a clinical challenge with limited options for treatment; however, ILI and

Due to its relatively good local response rates and tolerable adverse event profile, intralesional therapy may be a treatment option for select patients with